Oslo, 20 October 2022 - Navamedic ASA (OSE: NAVA) today announces the launch of
ForlaxGO® across pharmacies in Norway, Sweden, Finland and Denmark. ForlaxGO® is
a unique product that relieves the symptoms of occasional constipation in adults
and children above 8 years of age. The launch is part of a long-term agreement
with Ipsen Consumer HealthCare, a reputable French pharmaceutical company,
whereby Navamedic is the exclusive partner in the Nordics.
"Following the long-term agreement with Ipsen and the subsequent launch of
SmectaGO® in February, we are pleased to announce the launch of ForlaxGO®, the
second product launch stemming from this agreement. With only 20 percent of
those suffering from constipation and other gastro conditions seeking treatment,
we believe we can improve people's lives by making products such as ForlaxGO®
accessible and increasing awareness of treatment options. ForlaxGO® is already
well established on the European continent, and we are confident that our local
insight and market access will drive the development of this treatment category
in the Nordics," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
ForlaxGO® is an on-the-go, ready-to-drink suspension thatrelieves the symptoms
ofoccasional constipation in adults and children above 8 years of age. The main
component of the product is macrogol, which provides a sense of natural
relief.ForlaxGO® is presented as a ready-to-use solution in a single-dose sachet
and can be bought at pharmacies without a prescription.
Constipation is defined as slow, hard or infrequent stools. The problem is
widespread among older people and is three times as common among women as men.
20 percent of the population experience or live with constipation, and about 10
percent use laxatives.
"We continue to accelerate growth by launching new products such as ForlaxGO®,
underpinning our target of 20 percent annual organic growth and the mid-term
ambition of building a NOK 1 billion company," says Kathrine Gamborg Andreassen,
CEO of Navamedic ASA.
For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com
Lars Hjarrand, CFO, Navamedic
Mobile: +47917 62 842
E-mail: lars.hjarrand@navamedic.com
Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com
This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.